Omapone Inj. (TPN, Total Parenteral Nutrition)

Fixed Dose Combination drug, indicated for Hypertension with Clinical trials phase Ⅰ & Ⅲ

Fixed Dose Combination drug, indicated for Hypertension with dyslipidemia with Clinical trials phase Ⅰ & Ⅲ

- New Chemical Entity with P-CAB(Potassium Competitive Acid Blocker) mechanism
- Already became No.1 A2B product in Korean market since its launch in 2019 and to be expected to achieve $100m sales in Korean domestic market - Medicine indicated for GERD, EE, NERD, GU, H. Pylori- Out licensed to Chin...

Infections caused by susceptible microorganism

Fixed Dose Combination drug, indicated for Hypertension with Clinical trials phase Ⅰ & Ⅲ

Acute bacterial sinusitis, acute bacterialexacerbation of chronic bronchitis,community acquired pneumonia and so on

Pleural mesothelioma and non-small cell lung cancer

Fixed Dose Combination drug, indicated for Gastroduodenal ulcer, gastritis, reflux esophagitis

Fixed Dose Combination drug, indicated for Hyperlipidemia Primary hypercholesterinemia with Clinical trials phase Ⅰ & Ⅲ

Insomnia, Non-addictive and helps staying asleep longer

Serious infections by gram-positive bacteria

Non-small cell lung cancer and pancreatic cancer

Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)